文献速递白血病

EVI1重排白血病中被劫持超级增强子复合物的治疗靶点鉴定

Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
PubMed 文献 · Leukemia · 2021-04-28

本研究旨在解析3q21q26异常急性髓系白血病(3q-AML)中G2DHE超级增强子结合转录因子复合物的关键组分。研究发现CEBPA和RUNX1结合位点富集且对G2DHE功能关键,ChIP-SICAP鉴定出PARP1和IKZF1等染色质互作蛋白。PARP1抑制可降低EVI1表达及EVI1-G2DHE互作频率,3q-AML细胞对PARP抑制剂高度敏感并出现分化、凋亡增加及CD34+细胞耗竭。

要点

  • CEBPA和RUNX1结合位点富集且对3q-AML中G2DHE功能关键
  • PARP1参与致癌超级增强子形成,抑制PARP1降低EVI1表达
  • 3q-AML细胞对PARP抑制剂高度敏感,PARP1为潜在治疗靶点

核心结论

  • 整合分析3q-AML超级增强子复合物鉴定出CEBPA和RUNX1相关蛋白,并提名PARP1为EVI1+3q-AML的潜在新治疗靶点。

研究设计与样本

  • 基础研究,在3q-AML细胞中鉴定G2DHE结合的CEBPA和RUNX1位点,并用ChIP-SICAP检测RUNX1和CEBPA的染色质互作蛋白。

主要发现

  • CEBPA和RUNX1的多个结合位点在3q-AML细胞中富集且对G2DHE功能关键。
  • ChIP-SICAP在3q-AML中检测到RUNX1和CEBPA的染色质互作蛋白,包括PARP1和IKZF1。
  • PARP1抑制导致EVI1表达降低及EVI1-G2DHE互作频率下降。
  • 3q-AML细胞对PARP抑制剂高度敏感,表现为分化率和凋亡率升高及CD34+细胞耗竭。

临床怎么用

  • PARP抑制剂可能作为EVI1+3q-AML的候选治疗策略,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Deregulation of the EVI1 proto-oncogene by the GATA2 distal hematopoietic enhancer (G2DHE) is a key event in high-risk acute myeloid leukemia carrying 3q21q26 aberrations (3q-AML). Upon chromosomal rearrangement, G2DHE acquires characteristics of a super-enhancer and causes overexpression of EVI1 at 3q26.2. However, the transcription factor (TF) complex of G2DHE remains poorly characterized. The aim of this study was to unravel key components of G2DHE-bound TFs involved in the deregulation of EVI1. We have identified several CEBPA and RUNX1 binding sites to be enriched and critical for G2DHE function in 3q-AML cells. Using ChIP-SICAP (ChIP followed by selective isolation of chromatin-associated proteins), a panel of chromatin interactors of RUNX1 and CEBPA were detected in 3q-AML, including PARP1 and IKZF1. PARP1 inhibition (PARPi) caused a reduction of EVI1 expression and a decrease in EVI1-G2DHE interaction frequency, highlighting the involvement of PARP1 in oncogenic super-enhancer formation. Furthermore, 3q-AML cells were highly sensitive to PARPi and displayed morphological changes with higher rates of differentiation and apoptosis as well as depletion of CD34 + cells. In summary, integrative analysis of the 3q-AML super-enhancer complex identified CEBPA and RUNX1 associated proteins and nominated PARP1 as a potential new therapeutic target in EVI1 + 3q-AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kiehlmeier S, Rafiee MR, Bakr A, et al. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia. Leukemia. 2021. PMID: 33911178. doi:10.1038/s41375-021-01235-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。